Skip to main content

Peer Review reports

From: Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

Original Submission
27 Mar 2017 Submitted Original manuscript
25 Apr 2017 Reviewed Reviewer Report - A. Ariani
16 May 2017 Reviewed Reviewer Report - Rajesh Bhagat
8 Jun 2017 Author responded Author comments - Yosuke Tanaka
Resubmission - Version 2
8 Jun 2017 Submitted Manuscript version 2
26 Jun 2017 Reviewed Reviewer Report - A. Ariani
12 Jul 2017 Reviewed Reviewer Report - Martina Sterclova
24 Jul 2017 Author responded Author comments - Yosuke Tanaka
Resubmission - Version 3
24 Jul 2017 Submitted Manuscript version 3
27 Jul 2017 Reviewed Reviewer Report - A. Ariani
29 Jul 2017 Reviewed Reviewer Report - Martina Sterclova
8 Aug 2017 Author responded Author comments - Yosuke Tanaka
Resubmission - Version 4
8 Aug 2017 Submitted Manuscript version 4
16 Aug 2017 Reviewed Reviewer Report - A. Ariani
25 Aug 2017 Reviewed Reviewer Report - Martina Sterclova
26 Oct 2017 Author responded Author comments - Yosuke Tanaka
Resubmission - Version 5
26 Oct 2017 Submitted Manuscript version 5
Publishing
24 Nov 2017 Editorially accepted
13 Dec 2017 Article published 10.1186/s12890-017-0523-2

You can find further information about peer review here.

Back to article page